Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0000950170-25-068039·Maze Therapeutics, Inc.
Schedule 13G ownership disclosure
Maze Therapeutics Inc
Common Stock, $0.001 par value per share · CUSIP: 578784100
Event date: 2025-01-31
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Third Rock Ventures IV, L.P.
Shares: 6,073,958 · Class: 13.9%
- Third Rock Ventures GP IV, L.P.
Shares: 6,073,958 · Class: 13.9%
- TRV GP IV, LLC
Shares: 6,073,958 · Class: 13.9%
- Third Rock Ventures V, L.P.
Shares: 950,800 · Class: 2.2%
- Third Rock Ventures GP V, L.P.
Shares: 950,800 · Class: 2.2%
- TRV GP V, LLC
Shares: 950,800 · Class: 2.2%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000950170-25-068039
- Form type
- SCHEDULE 13G
- Filer
- Maze Therapeutics, Inc.
- CIK
- CIK 1842295
- Filed
- May 09, 2025
- Reporting period
- Jan 31, 2025
- Description
- Schedule 13G beneficial ownership